-
Health Equity Considerations in Economic Evaluation: Comparative Acceptability and Application Across European HTA Bodies
Sep 9, 2025, 16:22 PM -
Beyond the Mean: Do Distribution-Based Metrics Offer Greater Insight Into Predictors of Societal Health Preferences? A Secondary Analysis of 42 EQ-5D-5L Value Sets
Sep 9, 2025, 16:22 PM -
Addressing the Impact of Alzheimer’s Disease on Care Capacity in the Netherlands: Implications for Health Technology Assessment
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization and Disease Progression in Patients With Primary Hyperoxaluria: A Retrospective Cohort Study
Sep 9, 2025, 16:22 PM -
Real-World Evidence in European Orphan Drug Submissions and the Impact on Reimbursement Success
Sep 9, 2025, 16:22 PM -
German HTA Outcomes for Rare Disease Drugs When Orphan Designation Does Not Legally Determine Added Benefit
Sep 9, 2025, 16:22 PM -
Acceptance of Artificial Intelligence in Evidence and Dossier Development by Global HTA Agencies
Sep 9, 2025, 16:22 PM -
Exploring Nordic Real-World Evidence Sources for a PICO Assessment of a Hypothetical Oncology Drug and Medical Device Product
Sep 9, 2025, 16:22 PM -
Procalcitonin-Guided Antimicrobial Stewardship for Sepsis and Lower Respiratory Tract Infections: A Budget Impact Analysis for the Perspective of the Patients in India
Sep 9, 2025, 16:22 PM -
The Role of Technological Innovation and Policy in the Evolution of Care Models in Italy
Sep 9, 2025, 16:22 PM -
A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Minocycline Intravenous for the Treatment of Serious Infections Due to Multidrug-Resistant Acinetobacter baumannii in Jordan
Sep 9, 2025, 16:22 PM -
Requirements for Payer Recognition of Disease-Modifying Effect in New Drug Launches
Sep 9, 2025, 16:22 PM -
The Economic Burden of Parkinson's Disease in the Netherlands: From Societal Impact to Investments in Health Solutions
Sep 9, 2025, 16:22 PM -
Economic Evaluation in Alzheimer’s Disease: A Systematic Review
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Artificial Intelligence Interventions for Musculoskeletal Disorders: Systematic Review
Sep 9, 2025, 16:22 PM -
Evaluating the Role of Disease-Specific Patient-Reported Outcomes in HTA Submissions for Rare Conditions: A Comparative Case Study of Narcolepsy and Phenylketonuria
Sep 9, 2025, 16:22 PM -
Characterizing Comorbidities and Co-Occurring Conditions in Adults with Generalized Anxiety Disorder in the United States
Sep 9, 2025, 16:22 PM -
Feasibility of Building a Generic Partitioned Survival Model for Oncology: Essential Components and Technical Implementation
Sep 9, 2025, 16:22 PM -
Design Operating Characteristics in a Noninterventional Study Framework
Sep 9, 2025, 16:22 PM
